Thornburg Investment Management Inc. Sells 15,592 Shares of Insmed, Inc. $INSM

Thornburg Investment Management Inc. cut its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 22.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,248 shares of the biopharmaceutical company’s stock after selling 15,592 shares during the period. Thornburg Investment Management Inc.’s holdings in Insmed were worth $5,359,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of INSM. ORG Partners LLC lifted its stake in Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 196 shares during the period. Hilltop National Bank purchased a new position in shares of Insmed during the second quarter valued at approximately $28,000. FNY Investment Advisers LLC bought a new position in Insmed during the second quarter valued at approximately $33,000. LRI Investments LLC purchased a new stake in Insmed in the second quarter worth approximately $59,000. Finally, Strategic Investment Solutions Inc. IL purchased a new stake in Insmed in the first quarter worth approximately $79,000.

Insider Transactions at Insmed

In related news, Director Elizabeth M. Anderson sold 5,000 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $204.58, for a total value of $1,022,900.00. Following the sale, the director directly owned 58,729 shares in the company, valued at approximately $12,014,778.82. The trade was a 7.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Leo Lee sold 75,000 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $195.90, for a total value of $14,692,500.00. Following the transaction, the director owned 54,677 shares of the company’s stock, valued at $10,711,224.30. This represents a 57.84% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 257,922 shares of company stock valued at $44,556,283. 3.00% of the stock is owned by insiders.

Insmed Price Performance

Shares of Insmed stock opened at $204.51 on Thursday. The stock’s 50-day simple moving average is $171.50 and its 200-day simple moving average is $128.13. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $209.77. The company has a market capitalization of $43.62 billion, a price-to-earnings ratio of -35.82 and a beta of 1.05.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The company had revenue of $142.34 million for the quarter, compared to analysts’ expectations of $114.33 million. During the same period last year, the business earned ($1.27) earnings per share. The company’s quarterly revenue was up 52.4% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. As a group, analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. UBS Group boosted their target price on shares of Insmed from $194.00 to $223.00 and gave the company a “buy” rating in a research note on Friday, October 31st. JPMorgan Chase & Co. increased their target price on Insmed from $111.00 to $135.00 and gave the company an “overweight” rating in a report on Wednesday, August 20th. Guggenheim boosted their price target on Insmed from $125.00 to $172.00 and gave the company a “buy” rating in a research note on Monday, September 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a report on Wednesday, October 8th. Finally, TD Cowen upped their target price on shares of Insmed from $223.00 to $231.00 and gave the company a “buy” rating in a report on Thursday, November 20th. Nineteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Insmed has a consensus rating of “Moderate Buy” and a consensus price target of $175.53.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.